Eli Lilly and Company $LLY Holdings Raised by Prudential PLC

Prudential PLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 11.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 71,965 shares of the company’s stock after buying an additional 7,412 shares during the period. Prudential PLC’s holdings in Eli Lilly and Company were worth $56,099,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC raised its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the period. Covestor Ltd increased its stake in Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after buying an additional 85 shares during the period. Kaufman Rossin Wealth LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter valued at $242,000. Finally, Opes Wealth Management LLC grew its holdings in shares of Eli Lilly and Company by 6.6% during the 1st quarter. Opes Wealth Management LLC now owns 337 shares of the company’s stock valued at $278,000 after acquiring an additional 21 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 1.8%

Shares of LLY opened at $1,048.90 on Thursday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market cap of $991.61 billion, a PE ratio of 68.56, a PEG ratio of 1.21 and a beta of 0.43. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,055.59. The stock has a 50 day simple moving average of $844.09 and a 200-day simple moving average of $784.22.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue was up 53.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Analyst Ratings Changes

A number of research firms have issued reports on LLY. Scotiabank initiated coverage on shares of Eli Lilly and Company in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 target price for the company. UBS Group upped their target price on Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, Daiwa Capital Markets lifted their price target on Eli Lilly and Company from $700.00 to $940.00 in a research report on Monday, November 10th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,027.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.